[link removed] [link removed] [link removed] [link removed]

Email not displaying correctly? View it in your browser. ([link removed])

[link removed]
Issue 1,825: July 30, 2025
Top Stories
* Large U.S. study of nirsevimab (Beyfortus, Sanofi) shows high real-world effectiveness in protecting infants against RSV-associated respiratory disease (#IZX1)
* New! CDC releases at-a-glance resources for RSV products to help you prepare for respiratory virus season. (#IZX2)
* HHS Secretary accepts June ACIP recommendation not to use preservative-containing seasonal influenza vaccines (#IZX3)
* National Immunization Awareness Month starts August 1. Use these resources to encourage vaccination. (#IZX4)
* Confirmed measles cases in 2025 increase to 1,319 across 39 states; public health officials urge vaccination (#IZX5)
* "Will Adults Need Additional Pneumococcal Conjugate Vaccines in the Future?” Watch the 1-minute answer, part of the Ask the Experts Video Series on YouTube. (#IZX6)
* Vaccines in the news (#IZX7)


Immunize​.org Website and Clinical Resources
* Spotlight on the Website: Immunize​.org’s "Official Release Repository" (#IZX8)


Featured Resources
* What vaccinators are sporting during National Immunization Awareness Month, from the Immunize​.org shop! (#IZX9)


Notable Publications
* “Change in Influenza Vaccine Uptake Among Adults in the United States from May 2020 to October 2024” published in PLOS Global Public Health (#IZX10)
* “Disparities in Nirsevimab Uptake Across a Pediatric Primary Care Network” published in Pediatrics (#IZX11)


Upcoming Events
* NFID hosts webinar titled “Communication Strategies to Build Trust and Address Misinformation” on August 6 at 2:00 p.m. (ET); CE credit offered (#IZX12)
* Virtual: Register for Immunize​.org Website Office Hours. Ask questions and learn about the “Official Guidance” (state resources) web section on Immunize​.org on August 6 at 4:00 p.m. (ET) or August 7 at 12:00 p.m. (ET). Recorded sessions archived. (#IZX13)


Editorial Information (#Editorial)
------------------------------------------------------------
Top Stories
------------------------------------------------------------
Large U.S. study of nirsevimab (Beyfortus, Sanofi) shows high real-world effectiveness in protecting infants against RSV-associated respiratory disease

In its July 22 issue, Pediatrics published Effectiveness of Nirsevimab Against RSV and RSV-Related Events in Infants ([link removed]) , including a video abstract. Nirsevimab (Beyfortus, Sanofi) preventive antibody product demonstrated strong effectiveness in protecting infants against RSV. Infants who received nirsevimab and still developed RSV disease had fewer medical visits and hospitalizations compared to those who were not immunized. RSV hospitalizations fell by 98% compared to unimmunized infants. The study excluded infants whose mothers received RSV vaccine during pregnancy to clearly measure nirsevimab’s effect. Portions of the abstract appear below.

The study included 31 900 infants; 15 647 (49.1%) received nirsevimab. There were 35 RSV LRTD [lower respiratory-tract disease] episodes (6.10/1000 person-years) among nirsevimab-immunized infants vs 462 (58.51/1000 person-years) among nonimmunized infants. Nirsevimab effectiveness was 87.2% . . . against RSV LRTD, 98.0% . . . against hospitalized RSV LRTD, and 71.0% . . . against PCR-confirmed RSV. Nirsevimab-immunized infants with RSV LRTD had fewer encounters . . . and lower odds of hospitalization . . . than nonimmunized infants. . . .

Nirsevimab was highly effective in protecting infants against RSV-associated LRTD as well as against milder RSV infection. Nirsevimab-immunized infants with RSV LRTD had significantly fewer medical encounters and were less likely to be hospitalized than were nonimmunized infants.

[link removed]

The video abstract is available by clicking the graphic above.

Plan now to ensure all eligible infants age 8 months and younger receive nirsevimab when its use resumes in October.
Back to top (#Top)

------------------------------------------------------------
New! CDC releases at-a-glance resources for RSV products to help you prepare for respiratory virus season.

The CDC released four new at-a-glance resources for healthcare professionals on RSV prevention products. Each 2-page document addresses a single product. Use these resources to help your clinical team prepare for RSV prevention in adults and infants this fall. These materials are available on the CDC’s main Respiratory Syncytial Virus (RSV) Immunizations ([link removed]) main page and include the following documents:
* CDC: Abrysvo ([link removed]) (PDF)
* CDC: Arexvy ([link removed]) (PDF)
* CDC: mResvia ([link removed]) (PDF)
* CDC: Nirsevimab ([link removed]) (PDF)

[link removed]

Related Links
* CDC: Respiratory Syncytial Virus (RSV) Immunizations ([link removed]) main page
* Immunize​.org: Vaccines A–Z: RSV (Respiratory Syncytial Virus) ([link removed]) main page

Back to top (#Top)
------------------------------------------------------------
HHS Secretary accepts June ACIP recommendation not to use preservative-containing seasonal influenza vaccines

On July 23, the HHS secretary accepted the ACIP recommendation ([link removed]) for the use of 2025–26 seasonal influenza vaccines that do not contain thimerosal as a preservative. The HHS decision follows the June 26 ACIP vote.

CDC’s “Thimerosal and Vaccines” web page currently states: “There is no evidence of harm caused by the low doses of thimerosal in vaccines, except for minor reactions like redness and swelling at the injection site.” Only about 4–5% of seasonal influenza vaccine doses administered in the most recent influenza season came from preservative-containing multidose vials.

Two other ACIP recommendations voted on in June are still under review by HHS and await acceptance to become official policy:
* Annual influenza vaccination for all people age 6 months and older
* Clesrovimab (Enflonsia, Merck) as an option for RSV prevention in infants

Related Links
* HHS: HHS Adopts ACIP Recommendation to Remove Thimerosal from All U.S. Influenza Vaccines ([link removed]) (7/23/25)
* CDC: Thimerosal and Vaccines ([link removed]) web page (updated December 2024)
* Immunize​.org: Vaccines A–Z: Influenza ([link removed]) main page
* Immunize​.org: Thimerosal: Resources & Information ([link removed])
* American Academy of Pediatrics: Vaccine Ingredients: Frequently Asked Questions ([link removed]) (7/15/2025)
* American Pharmacists Association: Thimerosal: Quality Evidence of No Harm ([link removed]) (6/24/2025)
* Children’s Hospital of Philadelphia, Vaccine Education Center: Vaccine Ingredients: Thimerosal ([link removed]) (6/1/2020)

Back to top (#Top)
------------------------------------------------------------
National Immunization Awareness Month starts August 1. Use these resources to encourage vaccination.

August is National Immunization Awareness Month ([link removed]) (NIAM). This annual observance highlights the importance of protecting people of all ages against vaccine-preventable diseases through on-time vaccination. This year, NIAM serves as a focal point to share trustworthy, credible information about the importance of staying up to date with routine immunizations.

Multiple partners offer resources, including social media messaging that you can use in your NIAM communication.
* Voices for Vaccines' (VFV) NIAM web page ([link removed]) includes key messages and sample social media content to grab the public's attention on immunizations. VFV encourages its partners to share these messages and resources using the hashtag #NIAM2025.
* Immunize Canada and Vaccine Ambassadors partnered on an NIAM campaign ([link removed] ) , which includes images, posters, and social media content
* Vaccinate Your Family's #FirstDayVax campaign ([link removed]) reminds families that vaccines should be part of every back-to-school checklist. Find the shareable assets in the #FirstDayVax toolkit ([link removed]) , also available in Spanish ([link removed]) .

[link removed]

During NIAM, encourage your patients to schedule appointments to get up to date on annual exams and recommended vaccines. Research shows that healthcare providers remain the most trusted source of vaccine information for parents and patients.

Back to top (#Top)
------------------------------------------------------------
Confirmed measles cases in 2025 increase to 1,319 across 39 states; public health officials urge vaccination

As of July 23, CDC reported 1,319 confirmed measles cases ([link removed]) in 2025 in 39 states. Among confirmed cases of all ages, 13% were hospitalized. Among those younger than age 5 years, 29% were hospitalized.

CDC only requires reporting of laboratory-confirmed measles cases. Cases without laboratory testing for confirmation are not included in these numbers. Actual numbers of cases are, therefore, higher than confirmed case counts.

A map of 2025 measles cases ([link removed]) in the contiguous United States, as of July 24, from the Johns Hopkins International Vaccine Access Center ([link removed]) , appears below. The U.S. Measles Tracker ([link removed]) website includes state and county-level data.

[link removed]

Immunize​.org offers measles-related resources for the public on several of our affiliated websites:
* VaccineInformation​.org: Measles ([link removed]) web page
* LetsGetRealAboutVaccines​.org: Measles ([link removed]) web page
* Immunize​.org: Vaccines A–Z: Measles ([link removed]) main page

Another credible source is the American Academy of Pediatrics’ website for parents on measles ([link removed]) .
[link removed]
Related Links
* CDC: Measles Cases and Outbreaks ([link removed]) main page
* CDC: Be Ready for Measles Toolkit ([link removed])
* Center for Outbreak Response Innovation: Measles Outbreak Response ([link removed]) main page
* Immunize​.org: Vaccines A–Z: Measles ([link removed]) main page
* Immunize​.org: Ask the Experts: MMR (Measles, Mumps, and Rubella) ([link removed]) web page

Back to top (#Top)
------------------------------------------------------------
"Will Adults Need Additional Pneumococcal Conjugate Vaccines in the Future?” Watch the 1-minute answer, part of the Ask the Experts Video Series on YouTube.

This week, our featured episode from the Ask the Experts Video Series is titled Will Adults Need Additional Pneumococcal Conjugate Vaccines in the Future? ([link removed]) The video briefly explains that those vaccinated against pneumococcal disease at younger ages may eventually be recommended to receive a future PCV dose to sustain protection later in life.

The 1-minute video is available on our YouTube channel ([link removed]) , along with our full collection of quick video answers to popular Ask the Experts ([link removed]) questions.

[link removed]

Like, follow, and share Immunize​.org’s social media accounts and encourage colleagues and others interested in vaccination to do likewise.
* Facebook at ImmunizeOrg ([link removed])
* Instagram at ImmunizeOrg ([link removed])
* LinkedIn at ImmunizeOrg ([link removed])
* YouTube at ImmunizeOrg ([link removed])

Back to top (#Top)
------------------------------------------------------------
Vaccines in the news

These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
* CNN: RFK Jr. Signs Off on Thimerosal-Free Flu Vaccines, Despite No Evidence of Harm from Preservative ([link removed]) (7/23/25)
* BBC: How Canada Became the Centre of a Measles Outbreak in North America ([link removed]) (7/22/25)
* NBC: Day Care Measles Exposure Forces Iowa Family to Take Weeks off Work for Baby: ‘It Only Takes One’ ([link removed]) (7/17/25)

Back to top (#Top)
------------------------------------------------------------
Immunize​.org Website and Clinical Resources
------------------------------------------------------------
Spotlight on the Website: Immunize​.org’s "Official Release Repository"

Do you ever need to locate vaccine-related communications or announcements from ACIP, CDC, or FDA? Immunize​.org gathers them in our Official Release Repository ([link removed]) web page within the "News & Updates" menu atop each page. 

The Official Release Repository ([link removed]) contains a searchable list of announcements from ACIP, CDC, and FDA dating back to 2015. Each document source (i.e., ACIP, CDC, FDA) is available at its own tab. Within the category, filters allow you to narrow your search by publication year, vaccine or disease type, or patient age group.

To access the repository: 
* Click on the “News & Updates” tab on the menu bar found atop each page
* Select “Official Release Repository” on the left menu
* Select the “ACIP,” “CDC,” or “FDA” tab
* Filters you choose will indicate the number of available results. Click on the dropdown list to add a filter. Remove a filter by clicking “x” within the blue filter rectangle.


Back to top (#Top)
------------------------------------------------------------
Featured Resources
------------------------------------------------------------
What vaccinators are sporting during National Immunization Awareness Month, from the Immunize​.org shop!

The Immunize​.org Shop ([link removed]) offers a variety of products for your practice and to show how much you value vaccination. These may be especially helpful as you observe National Immunization Awareness Month in August.
* "Save Lives. Immunize." branded T-shirts: Featuring our logo on the front and on the back, our tag line: “Save Lives. Immunize.” The fabric is a super soft, premium triblend that doesn’t shrink or wrinkle with washing. Three designs include:
*
+ Unisex Tri-Blend Crew Tee ([link removed])
+ Women's Tri-Blend Tee ([link removed])
+ Unisex Tri-Blend 3/4 Raglan Tee ([link removed])
* “Vaccines Save Lives” pins ([link removed]) : Black enamel with gold lettering and edges, measuring 1.125" x 0.75". The pin features a stick-through post secured either by a rubber cap or a metal spring-lock cap (both provided).
* Wallet-sized Lifetime Immunization Record Cards ([link removed]) : Printed on rip-proof, smudge-proof, waterproof paper designed to last a lifetime. Sold in boxes of 250.
* Laminated booklets of the 2025 U.S. adult immunization schedule ([link removed]) : Printed in vivid color for easy reading, 16-page booklet measures 8 ½” x 11”. QR codes on the addendum page enable users to view or print updates made by CDC during the year.
* Immunization Techniques: Best Practices with Infants, Children, and Adults ([link removed]) (CD-ROM): From the California Department of Public Health, visual training on the techniques for proper vaccine administration.

[link removed]

Visit Shop Immunize​.org ([link removed]) to view pricing information and to place an order.

For more information, call 651-647-9009 or email [email protected] (mailto:[email protected]) .
Back to top (#Top)
------------------------------------------------------------
Notable Publications
------------------------------------------------------------
“Change in Influenza Vaccine Uptake Among Adults in the United States from May 2020 to October 2024” published in PLOS Global Public Health

In its July 16 issue, PLOS Global Public Health published Change in Influenza Vaccine Uptake Among Adults in the United States from May 2020 to October 2024 ([link removed]) . The study shows a concerning reduction in influenza vaccination during this period among people typically associated with higher vaccine uptake. A portion of the abstract appears below.

From 2020–2024, we conducted two distinct, cross-sectional surveys assessing influenza vaccine uptake among US adults. . . . We found that overall uptake decreased, with significant declines among demographic groups usually associated with higher vaccine uptake. Compared to 2022, individuals who were older (11% decrease), male (13%), White (7%), non-Hispanic (5%), or more educated (16%) were significantly less likely to receive the influenza vaccine in 2024. Changes in attitudes and intentions towards vaccination during and since the COVID-19 pandemic have been associated with several factors, including changes in perceived risk and the rise of vaccine-related mis- and disinformation. Targeted behavioral interventions can be used to shift attitudes, intentions, and eventually, behaviors, towards health-seeking behaviors like vaccination.
Back to top (#Top)

------------------------------------------------------------
“Disparities in Nirsevimab Uptake Across a Pediatric Primary Care Network” published in Pediatrics

In its July 17 issue, Pediatrics published Disparities in Nirsevimab Uptake Across a Pediatric Primary Care Network ([link removed]) , including a video abstract. The article highlights wide variation among 32 pediatric practices in use of nirsevimab (Beyfortus, Sanofi) among infants born between April and August before their first RSV season. These results show the importance of using reminder-recall and other clinic workflow strategies to improve timely immunization of eligible infants born in late spring and summer. Portions of the abstract appear below.

The objective of this study was to examine the distribution of nirsevimab to determine factors associated with nirsevimab receipt. . . .

Primary care attendee cohort of children younger than 8 months attending 1 of 32 pediatric primary care practices with almost universal nirsevimab availability [Eligible infants were born in April through the end of August, when they were unable to receive nirsevimab in the birth hospital and could not benefit from maternal RSV vaccination.]. . . .

A total of 2534 (35%) of 7208 eligible patients received nirsevimab, ranging from 20% to 65% across practices. . . .

In a large, diverse pediatric primary care network, 35% of eligible children received RSV prophylaxis despite near universal availability. Practice site, age, race, COI [Child Opportunity Index], and insurance were associated with nirsevimab receipt.

[link removed]

The video abstract is available by clicking on the graphic above.
Back to top (#Top)
------------------------------------------------------------
Upcoming Events
------------------------------------------------------------
NFID hosts webinar titled “Communication Strategies to Build Trust and Address Misinformation” on August 6 at 2:00 p.m. (ET); CE credit offered

NFID ([link removed]) will host a webinar titled Communication Strategies to Build Trust and Address Misinformation ([link removed]) at 2:00 p.m. (ET) on August 6. The panel includes NFID Medical Director Robert H. Hopkins Jr., MD; Coalition for Trust in Health & Science Executive Director Erin O’Malley; and NFID Director Jean-Venable (Kelly) R. Goode, PharmD, professor and director of the Community-Based Pharmacy Residency Program at Virginia Commonwealth University. Speakers will discuss the vaccine-preventable disease burden in the United States, strategies to identify mis- and disinformation, and implement practical communication strategies to help build trust with patients and caregivers and increase vaccine confidence.

CME and CNE credit are available. There is no fee to participate. Preregistration is required.

Register for the webinar ([link removed]) .

[link removed]

NFID hosts monthly webinars ([link removed]) to increase awareness of the importance of infectious disease prevention and treatment. CME, CNE, and CPE credits are available for select recordings. View all archived NFID webinars ([link removed]) .
Back to top (#Top)
------------------------------------------------------------
Virtual: Register for Immunize​.org Website Office Hours. Ask questions and learn about the “Official Guidance” (state resources) web section on Immunize​.org on August 6 at 4:00 p.m. (ET) or August 7 at 12:00 p.m. (ET). Recorded sessions archived.

To learn simple tips and tricks for using our website efficiently, please register for our next set of Website Office Hours on Wednesday, August 6 at 4:00 p.m. (ET) ([link removed]) or Thursday, August 7 at 12:00 p.m. (ET) ([link removed]) . The same content will be covered in both sessions.

We will open each 45-minute session with a short, live demonstration on navigating the Official Guidance ([link removed]) ("State Policies" and related resources) website section on Immunize​.org. This section was recently updated with 2025 data and can help those who want to know about state vaccination requirements for school and childcare. You can submit questions when you register or live on Zoom during the session.

Register today for Immunize​.org Website Office Hours (content is the same for both):
* Wednesday, August 6 at 4:00 p.m. (ET) ([link removed])
* Thursday, August 7 at 12:00 p.m. (ET) ([link removed])

The archive of previous Website Office Hours content ([link removed]) is posted at Immunize​.org’s "Webinars & Videos" page. These archived programs include Ask the Experts; Clinical Resources; Vaccine Information Statements (VISs); Affiliated Websites; Images, Webinars, Videos, & Social Media; Let's Get Real About Vaccines Website; News & Updates; Official Guidance Part 1 & 2; Publication Archives, Vaccine Timeline, & About Us; Travel Vaccines, Vaccine Confidence, & Addressing Concerns; and Vaccines A–Z.

Mark your calendar ([link removed])  for future Immunize​.org Website Office Hours.

Back to top (#Top)
------------------------------------------------------------
For more upcoming events, visit our Calendar of Events ([link removed]) .
Editorial Information
Editor-in-Chief
Kelly L. Moore, MD, MPH
Managing Editor
John D. Gr
äbenstein, RPh, PhD
Associate Editor
Sharon G. Humiston, MD, MPH
Writer/Publication Coordinator
Taryn Chapman, MS
Courtnay Londo, MA
Style and Copy Editor
Marian Deegan, JD
Web Edition Managers
Arkady Shakhnovich
Jermaine Royes
Contributing Writer
Laurel H. Wood, MPA
Technical Reviewer
Kayla Ohlde

About IZ Express
Immunize​.org welcomes redistribution of this issue of IZ Express or selected articles.
When you do so, please add a note that Immunize​.org is the source of the material and provide a link to this issue ([link removed]) .

IZ Express is supported in part by Grant No. NH23IP922654 from the National Center for Immunization and Respiratory Diseases, CDC. Its contents are solely the responsibility of Immunize​.org and do not necessarily represent the official views of CDC.

IZ Express Disclaimer (http:// [link removed])
ISSN: 2771-8085

This email was sent to [email protected] (mailto:[email protected])
why did I get this? ([link removed]) unsubscribe from this list ([link removed]) update subscription preferences ([link removed])
Immunize.org . 2136 Ford Parkway . Suite 5011 . Saint Paul, MN 55116 . USA